StemCell Institute Inc. (TYO:7096)
Japan · Delayed Price · Currency is JPY 1,017.00
-2.00 (-0.20%)
Aug 1, 2025, 3:30 PM JST
Theseus Pharmaceuticals Revenue
In the fiscal year ending March 31, 2025, StemCell Institute had annual revenue of 2.68B JPY with 7.98% growth. StemCell Institute had revenue of 639.00M in the quarter ending March 31, 2025, with 7.04% growth.
Revenue
2.68B
Revenue Growth
+7.98%
P/S Ratio
3.89
Revenue / Employee
22.90M
Employees
117
Market Cap
10.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 2.68B | 198.00M | 7.98% |
| Mar 31, 2024 | 2.48B | 390.00M | 18.65% |
| Mar 31, 2023 | 2.09B | 310.00M | 17.41% |
| Mar 31, 2022 | 1.78B | 372.00M | 26.40% |
| Mar 31, 2021 | 1.41B | -267.00M | -15.93% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.22B |
| Daiichi Sankyo Company | 1,924.68B |
| Takeda Pharmaceutical Company | 4,480.25B |
| HOYA Corporation | 876.09B |
| Otsuka Holdings | 2,393.18B |
| Terumo | 1,036.17B |
| Astellas Pharma | 1,944.99B |
| Shionogi & | 440.50B |